Categories: Washington Post

2 9/19/2018

One woman’s account of spinal cord stimulator skips realities of medical device safety in U.S.

6/27/2018

FDA approves new marijuana-derived drug, but was the evidence solid? Washington Post doesn’t say

4/17/2018

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

1/31/2018

Washington Post story on hyperbaric therapy for head injuries notes uncertain benefit–but not potential harms

12/12/2017

Gene therapy and hemophilia: Washington Post wisely tells readers ‘the study has some limitations’

11/14/2017

‘Regular painkillers work as well as opioids for fractures,’ but is this new information?

10/24/2017

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

8/31/2017

Washington Post’s otherwise well-reported story on ecstasy for PTSD skirts evidence discussion

7/18/2017

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

7/6/2017

Washington Post deftly examines lack of evidence for a fuzzy area of psychiatry: animal therapy

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

HealthNewsReview.org @HealthNewsRevu·

A week like this should teach you how/what to ignore: #COVID19 news & PR about studies in monkeys & mice...about studies of dishonesty & BMI…and about rating attractiveness of women with endometriosis!!! https://www.healthnewsreview.org/2020/08/crazy-week-of-pr-news-on-studies-should-teach-us-how-what-to-ignore/

Reply on Twitter 1291431630490480642 Retweet on Twitter 12914316304904806421 Like on Twitter 12914316304904806423 Twitter 1291431630490480642

Retweet on Twitter HealthNewsReview.org Retweeted

Elizabeth Kay Mendes @LizKayMendes·

“to project certainty where it simply does not exist is communication malpractice at a time like this and with a public health issue like this.” ⁦@garyschwitzer⁩ on ⁦@ContentScience⁩ https://review.content-science.com/covering-covid-19-vaccine-news-part-two-from-the-publisher-of-health-news-review/

Reply on Twitter 1291075113526464512 Retweet on Twitter 12910751135264645125 Like on Twitter 12910751135264645122 Twitter 1291075113526464512

Retweet on Twitter HealthNewsReview.org Retweeted

Elaine Schattner MD, MA @ESchattner·

In case you weren't aware: Prestigious journalism organizations and outlets take money from pharma, @garyschwitzer https://www.healthnewsreview.org/2020/08/drug-company-influence-on-journalism/#.XyrYGZeNvXA.twitter @HealthNewsRevu

Reply on Twitter 1291042197752745985 Retweet on Twitter 12910421977527459851 Like on Twitter 12910421977527459855 Twitter 1291042197752745985

Categories: Washington Post

One woman’s account of spinal cord stimulator skips realities of medical device safety in U.S.

FDA approves new marijuana-derived drug, but was the evidence solid? Washington Post doesn’t say

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

Washington Post story on hyperbaric therapy for head injuries notes uncertain benefit–but not potential harms

Gene therapy and hemophilia: Washington Post wisely tells readers ‘the study has some limitations’

‘Regular painkillers work as well as opioids for fractures,’ but is this new information?

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

Washington Post’s otherwise well-reported story on ecstasy for PTSD skirts evidence discussion

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

Washington Post deftly examines lack of evidence for a fuzzy area of psychiatry: animal therapy

Story Reviews

@HealthNewsRevu

Categories

Tags